| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 9.99% | $23.6M | 7.43M | Paradigm BioCapital Advisors LP | Dec 31, 2024 | |||
| Bain Capital Life Sciences Opportunities IV, L.P. | 9.99% | 0% | $21.8M | -$801K | 6.84M | -3.55% | Bain Capital Life Sciences Opportunities IV, L.P. | Mar 31, 2025 |
| Deep Track Capital, LP | 5.04% | $10.9M | 3.44M | Deep Track Capital, LP | Mar 31, 2025 | |||
| Logos Global Management LP | 4.7% | $10.2M | 3.21M | Logos Global Management LP | Mar 18, 2025 | |||
| Point72 Asset Management, L.P. | 2.3% | $4.91M | 1.54M | Point72 Asset Management, L.P. | Mar 31, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 231 | $2.26K | +$2.26K | $9.79 | 1 |
| 2025 Q2 | 70.5M | $300M | +$22.6M | $4.26 | 120 |
| 2025 Q1 | 65.9M | $248M | -$30.7M | $3.76 | 131 |
| 2024 Q4 | 71.3M | $415M | +$48.5M | $5.83 | 154 |
| 2024 Q3 | 58.7M | $700M | +$12.5M | $11.94 | 129 |
| 2024 Q2 | 57.9M | $626M | +$18.1M | $10.82 | 127 |
| 2024 Q1 | 56.1M | $635M | +$37.7M | $11.32 | 126 |
| 2023 Q4 | 57.5K | $806K | +$282K | $14.03 | 3 |
| 2023 Q3 | 47.3M | $584M | +$135M | $12.35 | 96 |
| 2023 Q2 | 36.4M | $329M | +$43.2M | $9.03 | 85 |
| 2023 Q1 | 33.4M | $116M | +$1.79M | $3.47 | 64 |
| 2022 Q4 | 33.3M | $81.6M | -$799K | $2.45 | 65 |
| 2022 Q3 | 33.3M | $92M | -$3.94M | $2.76 | 66 |
| 2022 Q2 | 34.2M | $139M | -$8.59M | $4.07 | 68 |
| 2022 Q1 | 36.3M | $155M | -$17.9M | $4.26 | 84 |
| 2021 Q4 | 38.4M | $359M | -$41.6M | $9.36 | 91 |
| 2021 Q3 | 36.3M | $1B | -$19.8M | $27.56 | 73 |
| 2021 Q2 | 37.4M | $1.05B | +$59M | $27.98 | 67 |
| 2021 Q1 | 35.2M | $1.16B | -$1.71M | $33.18 | 72 |
| 2020 Q4 | 34.8M | $1.64B | +$1.64B | $48.08 | 55 |